Real-world effectiveness of tezepelumab on clinical remission and small airway dysfunction in severe asthma: a 52-week prospective study - PubMed
2 hours ago
- #Severe Asthma
- #Clinical Remission
- #Oscillometry
- Tezepelumab in severe asthma leads to 100% elimination of severe exacerbations and complete oral corticosteroid withdrawal.
- Clinical remission was achieved by 77.4% of the overall evaluable cohort and 80.0% of those with baseline small airway dysfunction (SAD) after 12 months.
- No SAD remission was observed; patients with baseline SAD maintained persistent oscillometric abnormalities despite meeting clinical goals.
- Persistent mechanical abnormalities highlight the need for oscillometry to detect hidden residual disease in patients otherwise in clinical remission.
- Symptomatic and inflammatory recovery dissociates from physiological SAD remission in the SAD phenotype.